Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) will report its full year 2020 financial results on March 25, 2021, after market close. A conference call and audio webcast will follow at 1:30 PM Pacific / 4:30 PM Eastern to discuss these results and provide updates on the company’s developments, particularly regarding its lead product candidate NL-201, an immunotherapy aimed at improving tolerability and activity. Neoleukin utilizes advanced computational methods for its de novo protein therapeutics, addressing cancer and autoimmune diseases.

Positive

• Scheduled reporting of full year 2020 financial results, providing transparency to investors.
• Conference call to discuss financial results and corporate updates enhances investor communication.

Negative

• Current FDA clinical hold on NL-201 raises concerns about product development timelines.
• Uncertainties regarding cash forecasts and ability to advance product candidates may affect investor confidence.

SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday, March 25, 2021 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Date: March 25, 2021
Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 2666855
Webcast URL: http://investor.neoleukin.com/events

The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Safe Harbor / Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201 and planned development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, including related to the current FDA clinical hold on NL-201, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

When will Neoleukin Therapeutics release its full year 2020 financial results?

Neoleukin Therapeutics will release its full year 2020 financial results on March 25, 2021, after the close of markets.

What is NL-201 and its significance for Neoleukin Therapeutics?

NL-201 is Neoleukin's lead immunotherapy candidate designed to improve tolerability and effectiveness against cancer and autoimmune diseases.

How can I listen to the Neoleukin conference call regarding their financial results?

The conference call can be accessed on March 25, 2021, at 1:30 PM Pacific / 4:30 PM Eastern through the provided webcast URL.

What impact does the FDA clinical hold on NL-201 have on Neoleukin Therapeutics?

The FDA clinical hold on NL-201 delays its development and poses risks to Neoleukin's overall product advancement and market potential.